These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8861178)

  • 41. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
    Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
    Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Do enzyme inducers modify haloperidol decanoate rate of release?
    Pupeschi G; Agenet C; Levron JC; Barges-Bertocchio MH
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1323-32. PubMed ID: 7863019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.
    Beresford R; Ward A
    Drugs; 1987 Jan; 33(1):31-49. PubMed ID: 3545764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison.
    Eberhard G; Hellbom E
    Acta Psychiatr Scand; 1986 Sep; 74(3):255-62. PubMed ID: 3788652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of inpatient depot antipsychotic prescribing.
    Pabis DJ; Dorson PG; Crismon ML
    Ann Pharmacother; 1996 Dec; 30(12):1381-6. PubMed ID: 8968447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative bioavailability study of two haloperidol decanoate containing products.
    van Weringh G; Komen BJ; Thieme RE; van der Hoeven RT; Vos T
    Pharm World Sci; 1994 Dec; 16(6):243-7. PubMed ID: 7889022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study.
    Wistedt B; Koskinen T; Thelander S; Nerdrum T; Pedersen V; Mølbjerg C
    Acta Psychiatr Scand; 1991 Jul; 84(1):14-21. PubMed ID: 1681680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Intraindividual comparison of haloperidol decanoate and oxyprothepine in maintenance therapy in schizophrenic psychoses].
    Cesková E; Svestka J; Rysánek R
    Cesk Psychiatr; 1993 Jan; 89(1):11-4. PubMed ID: 8099534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy.
    arap Mengech HN; Wazome EG
    East Afr Med J; 1984 Jun; 61(6):435-8. PubMed ID: 6152736
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
    Wiles DH; McCreadie RG; Whitehead A
    Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Case report: increased patient response to intramuscular haloperidol decanoate following a change in needle length.
    Brahm NC; Washington NB
    J Pharm Pract; 2011 Dec; 24(6):561-3. PubMed ID: 22048930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome comparison of patients receiving oral or depot neuroleptic medication.
    Varner RV; Hays JR; Wagner AL; Averill P
    Psychol Rep; 2001 Aug; 89(1):169-74. PubMed ID: 11729538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.